Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer
About Aileron Therapeutics, Inc.
- NASDAQ: $ALRN
- Notified: $1.79
- 07:01 EDT
